Triple
T17269051
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Foreign Market Development Program |
E419203
|
entity |
| Predicate | relatedProgram |
P37
|
FINISHED |
| Object | Market Access Program |
E419202
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Market Access Program | Statement: [Foreign Market Development Program, relatedProgram, Market Access Program]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Market Access Program Context triple: [Foreign Market Development Program, relatedProgram, Market Access Program]
-
A.
Market Access Program
chosen
The Market Access Program is a U.S. Department of Agriculture export promotion initiative that helps expand foreign markets for American agricultural products through cost-sharing with producers and trade organizations.
-
B.
Market Access Group
The Market Access Group is a specialized working group focused on reducing trade barriers and improving market entry conditions for businesses under the Committee on Trade and Investment.
-
C.
Access to Medicines Program
The Access to Medicines Program is a Public Citizen initiative that advocates for affordable, equitable access to essential medicines worldwide by challenging high drug prices and restrictive pharmaceutical policies.
-
D.
340B Drug Pricing Program
The 340B Drug Pricing Program is a U.S. federal initiative that requires drug manufacturers to provide outpatient medications to eligible healthcare organizations at significantly reduced prices to support care for underserved patients.
-
E.
Medicaid Drug Rebate Program
The Medicaid Drug Rebate Program is a U.S. federal initiative that requires drug manufacturers to provide rebates to state Medicaid programs in exchange for Medicaid coverage of their outpatient prescription drugs, helping control costs for the program.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d886da626481908a14ce7830329a35 |
completed | April 10, 2026, 5:12 a.m. |
| NER | Named-entity recognition | batch_69e42f4803b48190894b3bb9a4970602 |
completed | April 19, 2026, 1:26 a.m. |
| NED1 | Entity disambiguation (via context triple) | batch_6a0179482a348190a00dd3cd5076431e |
completed | May 11, 2026, 6:38 a.m. |
Created at: April 10, 2026, 5:40 a.m.